tiprankstipranks
Advertisement
Advertisement

RARE Stock Latest News

Trump plans to fire FDA commissioner Marty Makary, WSJ reports
The FlyTrump plans to fire FDA commissioner Marty Makary, WSJ reports
4h ago
DYN
RNA
Ultragenyx price target lowered to $26 from $27 at Wedbush
PremiumThe Fly
Ultragenyx price target lowered to $26 from $27 at Wedbush
9h ago
RARE
Ultragenyx price target lowered to $43 from $52 at Guggenheim
PremiumThe Fly
Ultragenyx price target lowered to $43 from $52 at Guggenheim
9h ago
RARE
Ultragenyx Earnings Call: Growth, Gene Therapy and Risk
PremiumCompany Announcements
Ultragenyx Earnings Call: Growth, Gene Therapy and Risk
2d ago
RARE
Ultragenyx price target lowered to $43 from $44 at Barclays
PremiumThe Fly
Ultragenyx price target lowered to $43 from $44 at Barclays
10d ago
RARE
Is RARE a Buy, Before Earnings?
PremiumPre-EarningsIs RARE a Buy, Before Earnings?
11d ago
RARE
Ultragenyx price target raised to $67 from $50 at Morgan Stanley
Premium
The Fly
Ultragenyx price target raised to $67 from $50 at Morgan Stanley
22d ago
RARE
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
Premium
The Fly
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
25d ago
DYN
RNA
Ultragenyx BLA for UX111 Accepted for FDA Review
PremiumCompany Announcements
Ultragenyx BLA for UX111 Accepted for FDA Review
1M ago
8K
RARE
Ultragenyx UX111 AAV9 biologics license application accepted for FDA review
PremiumThe Fly
Ultragenyx UX111 AAV9 biologics license application accepted for FDA review
1M ago
RARE
Ultragenyx Wins FDA IND Clearance for UX016 Therapy
PremiumCompany Announcements
Ultragenyx Wins FDA IND Clearance for UX016 Therapy
1M ago
8K
RARE
Ultragenyx announces FDA clearance of UX016 investigational new drug application
PremiumThe Fly
Ultragenyx announces FDA clearance of UX016 investigational new drug application
1M ago
RARE
Ultragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa
PremiumCompany AnnouncementsUltragenyx Nears Key Inflection Point With Completed Phase 3 Gene Therapy Study in GSDIa
1M ago
RARE
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
Premium
The Fly
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
2M ago
EL
RL
Microsoft reinstated, Ralph Lauren upgraded: Wall Street’s top analyst calls
Premium
The Fly
Microsoft reinstated, Ralph Lauren upgraded: Wall Street’s top analyst calls
2M ago
RL
AJG
Shareholders Sue Mereo BioPharma (MREO) Over Brittle Bone Drug Claims
PremiumMarket News
Shareholders Sue Mereo BioPharma (MREO) Over Brittle Bone Drug Claims
2M ago
NVS
MREO
Ultragenyx downgraded to Neutral from Buy at Goldman Sachs
PremiumThe Fly
Ultragenyx downgraded to Neutral from Buy at Goldman Sachs
2M ago
RARE
Ultragenyx Facing Shareholder Lawsuit over Brittle Bone Disease Drug Claims
PremiumMarket News
Ultragenyx Facing Shareholder Lawsuit over Brittle Bone Disease Drug Claims
2M ago
RARE
Ultragenyx Announces Positive Phase 3 Results for DTX301
PremiumCompany Announcements
Ultragenyx Announces Positive Phase 3 Results for DTX301
2M ago
8K
RARE
Ultragenyx Phase 3 Enh3ance study showed statistically significant results
PremiumThe FlyUltragenyx Phase 3 Enh3ance study showed statistically significant results
2M ago
RARE
Ultragenyx price target lowered to $74 from $120 at JPMorgan
Premium
The Fly
Ultragenyx price target lowered to $74 from $120 at JPMorgan
2M ago
RARE
Controversial Prasad leaving FDA, NYT reports
Premium
The Fly
Controversial Prasad leaving FDA, NYT reports
2M ago
AZN
BMY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >